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Background
Patients who have had a first episode of unprovoked venous thromboembolism have 
a high risk of recurrence after anticoagulants are discontinued. Aspirin may be effec-
tive in preventing a recurrence of venous thromboembolism.
Methods
We randomly assigned 822 patients who had completed initial anticoagulant therapy 
after a first episode of unprovoked venous thromboembolism to receive aspirin, at a 
dose of 100 mg daily, or placebo for up to 4 years. The primary outcome was a recur-
rence of venous thromboembolism.
Results
During a median follow-up period of 37.2 months, venous thromboembolism re-
curred in 73 of 411 patients assigned to placebo and in 57 of 411 assigned to aspirin 
(a rate of 6.5% per year vs. 4.8% per year; hazard ratio with aspirin, 0.74; 95% con-
fidence interval [CI], 0.52 to 1.05; P = 0.09). Aspirin reduced the rate of the two 
prespecified secondary composite outcomes: the rate of venous thromboembolism, 
myocardial infarction, stroke, or cardiovascular death was reduced by 34% (a rate of 
8.0% per year with placebo vs. 5.2% per year with aspirin; hazard ratio with aspirin, 
0.66; 95% CI, 0.48 to 0.92; P = 0.01), and the rate of venous thromboembolism, 
myocardial infarction, stroke, major bleeding, or death from any cause was reduced 
by 33% (hazard ratio, 0.67; 95% CI, 0.49 to 0.91; P = 0.01). There was no significant 
between-group difference in the rates of major or clinically relevant nonmajor bleed-
ing episodes (rate of 0.6% per year with placebo vs. 1.1% per year with aspirin, P = 0.22) 
or serious adverse events.
Conclusions
In this study, aspirin, as compared with placebo, did not significantly reduce the rate 
of recurrence of venous thromboembolism but resulted in a significant reduction in 
the rate of major vascular events, with improved net clinical benefit. These results 
substantiate earlier evidence of a therapeutic benefit of aspirin when it is given to 
patients after initial anticoagulant therapy for a first episode of unprovoked venous 
thromboembolism. (Funded by National Health and Medical Research Council 
[Australia] and others; Australian New Zealand Clinical Trials Registry number, 
ACTRN12605000004662.)
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Patients who have had a first episode of unprovoked venous thromboembolism are at high risk for recurrence after anticoagu-
lant therapy is discontinued.1-4 Long-term treat-
ment with a vitamin K antagonist is very effective 
in preventing a recurrence of venous thrombo-
embolism while treatment continues5 but has not 
been shown to improve survival, is associated 
with a substantially increased risk of bleeding, and 
is inconvenient for patients.6-10 Consequently, 
many patients who have had a first episode of 
unprovoked venous thromboembolism discontin-
ue anticoagulant therapy after 3 to 6 months de-
spite recommendations to prolong therapy.5
Low-dose aspirin is a simple, inexpensive, and 
widely available treatment that is effective for 
the prevention of arterial vascular events and for 
the primary prevention of venous thromboembo-
lism in high-risk surgical patients.11-13 Aspirin 
may also be effective in preventing a recurrence 
of venous thromboembolism after a first event.14 
The objective of our study was to evaluate the 
efficacy of low-dose aspirin, as compared with 
placebo, in preventing a recurrence of venous 
thromboembolism in patients who had com-
pleted initial anticoagulation with warfarin after 
a first unprovoked episode of venous thrombo-
embolism.
Me thods
Study Design
The Aspirin to Prevent Recurrent Venous Throm-
boembolism (ASPIRE) study was a double-blind, 
randomized, placebo-controlled study of the use of 
low-dose aspirin in patients who had had a first-
ever unprovoked venous thromboembolism and 
who had completed initial anticoagulation thera-
py. We randomly assigned patients who had com-
pleted anticoagulation therapy to aspirin, at a dose 
of 100 mg daily, or placebo; randomization was 
performed through a central Web-based random-
ization system, with stratification according to cen-
ter and duration of initial oral anticoagulation 
therapy (≤26 weeks or >26 weeks). Enteric-coated 
aspirin, in 100-mg tablets, and matching placebo 
were provided without charge by Bayer Health-
Care Pharmaceuticals; the company played no other 
role in the study and was not involved in the col-
lection or analysis of the data or in the prepara-
tion of the manuscript. Patients were asked to take 
one tablet daily for a minimum of 2 years. The 
maximum duration of treatment was subsequent-
ly capped at 4 years.
Patients
Male and female patients were eligible for inclu-
sion if they were at least 18 years of age and had 
had a first unprovoked episode of objectively di-
agnosed symptomatic deep-vein thrombosis involv-
ing the popliteal vein or more proximal leg veins 
or an acute pulmonary embolism. Venous throm-
boembolism was considered to be unprovoked if 
it occurred in the absence of the following tran-
sient risk factors during the preceding 2 months: 
confinement to bed for more than 1 week, major 
surgery, trauma requiring a cast, pregnancy or the 
puerperium, and the use of the oral contraceptive 
pill or hormone-replacement therapy. All patients 
were required to have completed initial anticoagu-
lation therapy with heparin followed by warfarin 
(or an effective alternative anticoagulant). The du-
ration of the initial anticoagulation therapy had 
to be between 6 weeks and 24 months; however, it 
was recommended that a target international nor-
malized ratio of 2 to 3 be maintained with warfa-
rin therapy for 6 to 12 months.
Patients were not eligible for inclusion if the 
first unprovoked episode of venous thromboembo-
lism had occurred more than 2 years before en-
rollment; if they had an indication or contrain-
dication for the use of aspirin, other antiplatelet 
therapy, or a nonsteroidal antiinflammatory drug; 
if they had an indication for continuing oral anti-
coagulation therapy; or if they had other medical 
problems that would interfere with participation 
in the trial or limit life expectancy. A detailed de-
scription of the eligibility criteria is provided in the 
study protocol, available with the full text of this 
article at NEJM.org.
Follow-up
Patients attended follow-up visits at 1 month and 
6 months after randomization and every 6 months 
thereafter and were contacted by telephone or 
e-mail at the 3-month mark between visits. All 
patients who were enrolled after a first episode of 
unprovoked deep-vein thrombosis underwent ve-
nous ultrasound examination within 1 month af-
ter randomization to determine whether there was 
residual thrombus, in order to distinguish between 
residual thrombosis and a recurrence of throm-
bosis in subsequent assessments. Patients were 
instructed to report to their study center immedi-
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ately if symptoms suggestive of a recurrence of 
venous thromboembolism, bleeding, adverse ef-
fects of a study drug, or other clinically signifi-
cant changes developed. Information for each pa-
tient was included up to 4 years after enrollment 
or up to the scheduled final visit, whichever came 
first. The final visit was scheduled for each site 
during the first quarter of 2012, after the decision 
was made to close the trial.
Outcome Measures
The primary outcome of the study was a recur-
rence of venous thromboembolism, defined as a 
composite of symptomatic, objectively confirmed 
deep-vein thrombosis, nonfatal pulmonary embo-
lism, or fatal pulmonary embolism. Prespecified 
secondary outcomes were major vascular events (a 
composite of venous thromboembolism, myocar-
dial infarction, stroke, or cardiovascular death) and 
a measure of the net clinical benefit (a reduction 
in the rate of the composite of venous thromboem-
bolism, myocardial infarction, stroke, major bleed-
ing, or death from any cause). The risks of arte-
rial thrombosis and cardiovascular death are 
increased in patients with unprovoked venous 
thromboembolism15,16; these events were includ-
ed as secondary outcomes because they are clini-
cally important and are likely to be influenced by 
aspirin therapy. The diagnosis of a recurrence of 
venous thromboembolism required the presence 
of new symptoms and objective evidence on ap-
propriate imaging of new thrombosis that was 
not identified on previous imaging (as detailed in 
the study protocol). Pulmonary embolism was 
considered to be the cause of death if it was con-
firmed at autopsy or if death was preceded by a 
recurrence of symptomatic deep-vein thrombosis 
or pulmonary embolism and the cause of death 
could not be attributed to an alternative diagno-
sis. All episodes of venous thromboembolism, 
myocardial infarction, and stroke and the causes 
of death were adjudicated by an independent out-
come assessment committee whose members 
were unaware of the group assignments.
The primary safety outcome was bleeding, ei-
ther major or clinically relevant nonmajor bleeding. 
Major bleeding was defined as overt bleeding 
that was associated with a decrease in hemoglo-
bin of at least 2 g per deciliter or that necessi-
tated transfusion of 2 or more units of blood, 
involved a critical site (e.g., retroperitoneal or in-
tracranial bleeding), was disabling, required sur-
gical intervention, or contributed to death. Bleed-
ing episodes that did not meet the definition of 
major bleeding were considered to be clinically 
relevant only if they led to discontinuation of the 
study drug for more than 14 days. 
With plans developed a priori to subsequently 
pool the results of the ASPIRE trial and the War-
farin and Aspirin (WARFASA) trial,14 the protocols 
of the two trials were prospectively harmonized 
to ensure that the randomized treatments were 
identical and that eligibility criteria and outcome 
definitions were similar.
Study Oversight
The study protocol was written by members of the 
executive committee of the trial (see the Supple-
mentary Appendix, available at NEJM.org) and was 
approved by the University of Sydney human re-
search ethics committee, as well as by the ethics 
committees at each participating site. Written in-
formed consent was obtained from all patients be-
fore they underwent randomization. Clinical data 
were collected from electronic case-report forms 
with the use of an InForm clinical trial database 
(Oracle). The National Health and Medical Re-
search Council (NHMRC) Clinical Trials Centre 
was responsible for the collection, maintenance, 
integrity, and confidentiality of all data. The ex-
ecutive committee was responsible for all aspects 
of the conduct of the study. An independent safe-
ty and data monitoring committee reviewed the 
progress of all aspects of the study, including data 
on safety, and met annually. All primary and sec-
ondary events were adjudicated by an independent 
event adjudication committee whose members were 
unaware of the group assignments. The final analy-
sis plan and adjudication of all primary and sec-
ondary events were completed before unblinding 
of results according to group assignments. The 
analysis was performed at the NHMRC Clinical 
Trials Centre. The first draft of the manuscript was 
written by the first two authors and the last au-
thor, and all the authors contributed to the final 
manuscript and attest to the accuracy of the data 
and to the fidelity of the study to the protocol. 
No one who is not an author contributed to the 
manuscript.
Statistical Analysis
The ASPIRE study was originally designed to re-
cruit 3000 patients, which would have given the 
study 90% power to detect a relative-risk reduc-
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tion of 30% in the incidence of venous thrombo-
embolism with aspirin as compared with placebo, 
assuming an event rate of 7% per year in the pla-
cebo group, at a two-sided alpha level of 0.05. The 
study commenced in 2003, but because of slow 
recruitment, the target sample size was reduced 
in 2005 to 1500 patients with an expected dura-
tion of follow-up of 4 years, and plans were made 
(with interim trial results concealed) to combine 
the final results with those of the WARFASA trial14 
in a prospectively planned meta-analysis (Austra-
lian New Zealand Clinical Trials Registry number, 
ACTRN12611000684921). The ASPIRE study with 
the reduced sample size, when combined with the 
WARFASA study, had 80% power to detect a 30% 
reduction in the primary outcome of recurrence of 
venous thromboembolism (and the ASPIRE study 
alone had 80% power to detect a 32% reduction in 
the secondary outcome of all major vascular events). 
Recruitment closed in August 2011 because of de-
clining recruitment rates and limited resources, 
with an additional 12 months of follow-up planned 
for the last patient enrolled. The study follow-up 
was subsequently closed on March 31, 2012, after 
publication of the results of the WARFASA study, 
since it was believed that continuation of the trial 
would provide limited additional information if 
patients decided to switch to open-label aspirin 
on the basis of the results of the WARFASA trial.
In the primary analysis, we compared the two 
study groups with respect to the first occurrence 
of symptomatic and objectively confirmed deep-
vein thrombosis, nonfatal pulmonary embolism, 
or fatal pulmonary embolism using an intention-
to-treat approach and including events up to the 
final scheduled visit or up to a maximum of 4 years 
from the time of randomization. Data from pa-
tients who withdrew consent or who were lost to 
follow-up were censored at the time of the last 
follow-up assessment. All patients who stopped 
using the study drug continued to be followed and 
were included in the intention-to-treat analysis. 
Survival curves were estimated with the use of the 
Kaplan–Meier procedure and were compared with 
the use of log-rank tests.
In the primary analysis, treatment effects (with 
their 95% confidence intervals) were estimated 
by means of Cox regression analysis unadjusted 
for patient risk factors. In a similar analysis, we 
evaluated the effect of aspirin on prespecified 
secondary outcomes of major vascular events (a 
composite of venous thromboembolism, myocar-
dial infarction, stroke, or cardiovascular death) 
and net clinical benefit (reduction in the rate of 
the composite of venous thromboembolism, 
myocardial infarction, stroke, major bleeding, or 
all-cause death). Additional adjusted analyses of 
primary and secondary outcomes incorporated 
adjustment for prespecified characteristics (age, 
sex, smoking history, body-mass index [BMI], type 
of first unprovoked event, and duration of initial 
anticoagulation therapy). Interactions in Cox mod-
els were used to assess differences in the effect of 
aspirin across prespecified subgroups defined ac-
cording to age, sex, duration of initial anticoagu-
lation therapy, BMI, and type of first unprovoked 
event. In a time-to-event analysis that included only 
data from patients while they were receiving the 
study drug, data were censored at the time of the 
first discontinuation of the study drug for 90 or 
more days without recommencement and exclud-
ed outcome events that occurred after discontinu-
ation. In addition, we estimated the efficacy of 
aspirin in a fully adherent group by adjusting the 
treatment effect in the intention-to-treat analysis 
for the nonadherence rates averaged over the study 
period; the nonadherence rates were defined as 
the proportion of patients assigned to aspirin who 
discontinued it and the proportion of patients 
assigned to placebo who initiated antiplatelet or 
anticoagulation treatment.17 We combined the 
results from the ASPIRE and WARFASA studies 
by performing a meta-analysis of the log hazard 
ratios for the treatment effect on vascular events 
from each study weighted by their inverse vari-
ances.18 All analyses were performed with the 
use of SAS software, version 9.3 (SAS Institute).
R esult s
Patients
From May 2003 through August 2011, a total of 
822 patients underwent randomization at 56 sites 
in five countries (Fig. S1 in the Supplementary 
Appendix). Twelve patients (6 in the placebo group 
and 6 in the aspirin group) who were enrolled 
after a diagnosis of first unprovoked proximal 
deep-vein thrombosis and who were included in 
the analysis were subsequently found to be ineli-
gible after a review of the records: 8 (4 in each 
group) were found not to have had proximal deep-
vein thrombosis, 2 (1 in each group) had a pro-
voked venous thromboembolism, 1 in the placebo 
group had an indication for long-term anticoagu-
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lation, and 1 in the aspirin group had had a prior 
unprovoked venous thromboembolism. The base-
line characteristics of the patients did not differ 
significantly between the two groups (Table 1). A 
total of 447 patients enrolled in the ASPIRE study 
(54%) were men, the median age was 54 years, 
36% had a BMI (the weight in kilograms divided 
by the square of the height in meters) of 30 or 
higher, 15% reported that a first-degree relative 
had had a venous thromboembolism, 5% had a 
prior provoked venous thromboembolism, and 2% 
had active cancer (with non-melanoma skin can-
cer not included) at the time of randomization. 
The index event was proximal deep-vein throm-
bosis alone in 57% of the patients, pulmonary em-
bolism alone in 28%, and co-occurring deep-vein 
thrombosis and pulmonary embolism in 14%. A 
total of 73% of the patients had received anticoagu-
lation therapy for at least 6 months before random-
ization. The median time between the cessation of 
anticoagulation therapy and random assignment 
in the ASPIRE study was 7 days in both groups. 
The median duration of follow-up was 37.2 months.
Recurrent Venous Thromboembolism
During the follow-up period, the primary outcome 
of recurrent venous thromboembolism occurred 
in 73 of 411 patients (18%) assigned to placebo 
and 57 of 411 (14%) assigned to aspirin (a rate of 
6.5% per year vs. 4.8% per year; hazard ratio with 
aspirin, 0.74; 95% confidence interval [CI], 0.52 to 
1.05; P = 0.09) (Fig. 1A and Table 2). After adjust-
ment for baseline characteristics, the hazard ratio 
was 0.72 (95% CI, 0.51 to 1.01; P = 0.06) (Fig. S2 
in the Supplementary Appendix). There were 132 
episodes of nonfatal venous thromboembolism and 
2 cases of fatal venous thromboembolism in 130 
patients. One fatal pulmonary embolism occurred 
in each group. In 103 of the 134 cases (77%), the 
recurrent venous thromboembolism event was un-
provoked. Most of the recurrent deep-vein throm-
bosis events without a concurrent pulmonary 
embolism occurred in patients who had been en-
rolled with a diagnosis of first unprovoked deep-
vein thrombosis alone (70%, 57 of 82 events). Simi-
larly, 73% of the recurrent pulmonary embolism 
events (35 of 48 events) — with or without con-
current deep-vein thrombosis — occurred in pa-
tients who were enrolled with a diagnosis of un-
provoked pulmonary embolism (with or without 
deep-vein thrombosis). In 100 patients (58 in the 
placebo group and 42 in the aspirin group), venous 
thromboembolism recurred for the first time 
while they were receiving the study drug or with-
in 7 days after discontinuation of the study drug, 
whereas in 30 patients recurrences happened after 
discontinuation of the study drug. The analysis of 
data from patients while they were receiving the 
study drug showed a significant benefit with as-
Table 1. Baseline Characteristics of the Patients.*
Characteristic
Placebo 
(N = 411)
Aspirin 
(N = 411)
Age — yr 54±15.8 55±16.0
Male sex — no. (%) 221 (54) 226 (55)
Body-mass index — no. (%)†
<30 271 (66) 249 (61)
³≥30 140 (34) 160 (39)
Index event — no. (%)
Proximal deep-vein thrombosis only 232 (56) 236 (57)
Pulmonary embolism only 119 (29) 112 (27)
Both deep-vein thrombosis and pulmonary  
embolism
56 (14) 59 (14)
Duration of anticoagulation before randomization 
— no. (%)
<3 mo 4 (1) 5 (1)
3 to <6 mo 100 (24) 115 (28)
6 to <12 mo 266 (65) 258 (63)
≥12 mo 41 (10) 33 (8)
Time from completion of anticoagulation therapy 
to randomization — no. (%)
≤1 day 150 (36) 151 (37)
>1 to 7 days 71 (17) 71 (17)
>7 to 30 days 102 (25) 86 (21)
>30 days 88 (21) 103 (25)
Immediate anticoagulation therapy — no. (%)
Low-molecular-weight heparin 360 (88) 351 (85)
Unfractionated heparin 26 (6) 26 (6)
Other‡ 25 (6) 34 (8)
Subsequent anticoagulation therapy — no. (%)
Low-molecular-weight heparin 4 (1) 5 (1)
Warfarin 341 (83) 343 (83)
Other‡ 66 (16) 63 (15)
* Plus–minus values are means ±SD. None of these baseline characteristics dif-
fered significantly between the two groups.
† The body-mass index is the weight in kilograms divided by the square of the 
height in meters.
‡ Other anticoagulant therapy included other vitamin K antagonists, direct 
thrombin inhibitors, and factor Xa inhibitors.
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pirin (event rate of 7.6% per year with placebo vs. 
4.8% per year with aspirin; hazard ratio, 0.65; 
95% CI, 0.44 to 0.96; P = 0.03). The risk of a recur-
rence of venous thromboembolism was higher 
during the first year of follow-up (10.6% with 
placebo and 4.9% with aspirin) than in subse-
quent years (Fig. 1A). The treatment effects were 
similar within prespecified subgroups (Fig. S3 in 
the Supplementary Appendix).
Secondary Outcomes and Bleeding Events
The secondary outcome of major vascular events 
(a composite of venous thromboembolism, myo-
cardial infarction, stroke, or cardiovascular death) 
occurred in 88 patients assigned to placebo and 
62 assigned to aspirin (a rate of 8.0% per year vs. 
5.2% per year; hazard ratio with aspirin, 0.66; 
95% CI, 0.48 to 0.92; P = 0.01) (Fig. 1B). Clinically 
relevant bleeding occurred in 8 patients assigned 
to placebo (6 of whom had an episode of major 
bleeding) and 14 assigned to aspirin (8 of whom 
had an episode of major bleeding). In 2 patients, 
both in the placebo group, the major bleeding 
was fatal. The rates of all bleeding episodes did 
not differ significantly between the study groups. 
The analysis of net clinical benefit, defined as a 
reduction in the rate of the composite of venous 
thromboembolism, myocardial infarction, stroke, 
major bleeding, or death from any cause, showed 
that aspirin was associated with a reduction of 
33% in that composite outcome, with an event 
rate of 9.0% per year in the placebo group as 
compared with 6.0% per year in the aspirin 
group (hazard ratio with aspirin, 0.67; 95% CI, 
0.49 to 0.91; P = 0.01).
Adverse Events and Discontinuation 
of Study Drug
Adverse events leading to hospitalization occurred 
in 117 patients (28%) assigned to placebo and in 
102 patients (25%) assigned to aspirin (Table S1 in 
the Supplementary Appendix). During the follow-
up period, 132 patients assigned to placebo and 
117 patients assigned to aspirin discontinued the 
study drug (a rate of 15.1% per year vs. 11.9% per 
year; hazard ratio with aspirin, 0.79; 95% CI, 0.62 
to 1.01; P = 0.06) (data not shown). More patients 
in the placebo group than in the aspirin group 
(32 vs. 21) discontinued the study drug because of 
an indication for thromboprophylaxis, whereas 
more patients in the aspirin group than in the 
placebo group (14 vs. 2) discontinued the study 
drug owing to gastrointestinal adverse effects or 
bleeding (Table S2 in the Supplementary Appen-
dix). The median length of time that patients re-
ceived a study drug was 27.2 months, and the me-
dian total follow-up time was 37.2 months. A total 
of 68 patients assigned to placebo and 54 assigned 
to aspirin initiated open-label antiplatelet therapy 
or anticoagulation therapy before a defined vas-
cular event occurred. The times to permanent dis-
continuation of the study drug and commence-
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Figure 1. Risks of First Recurrent Venous Thromboembolism and Major 
Vascular Events.
Panel A shows the cumulative risk of a first recurrence of venous thrombo-
embolism, defined as symptomatic deep-vein thrombosis or pulmonary 
embolism. Panel B shows the cumulative risk of major vascular events  
(a composite of recurrent venous thromboembolism, myocardial infarction, 
stroke, or cardiovascular death). The inset shows the same data on an  
enlarged y axis.
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ment of antiplatelet or anticoagulant medications 
are shown in Figure S4 in the Supplementary Ap-
pendix. The combined rate of nonadherence to the 
study drug in the placebo and aspirin groups, av-
eraged over the study period, was 22%: 15% in the 
aspirin group discontinued the study drug and 
7% in the placebo group initiated antiplatelet or 
anticoagulation treatment (data not shown). The 
risk reduction with aspirin after adjustment of 
the intention-to-treat estimate for this nonadher-
ence rate was 33%, as compared with the unad-
justed intention-to-treat estimate of risk reduc-
tion of 26%.
Discussion
Although the results of the ASPIRE trial did not 
show a significant reduction in the primary out-
come of recurrent venous thromboembolism with 
aspirin as compared with placebo in patients who 
had had a first unprovoked venous thromboem-
bolism, it did show that aspirin reduced the sec-
ondary composite outcome of major vascular 
events by 34% without increasing bleeding and 
resulted in a significant net clinical benefit. Fur-
thermore, the estimated reduction of 26% (95% 
CI, −5 to 48) in the rate of recurrence of venous 
Table 2. Outcome Events, According to Study Group.*
Outcome Placebo (N = 411) Aspirin (N = 411)
Hazard Ratio with 
Aspirin (95% CI) P Value
no. of 
events
% per 
year
no. of 
events
% per 
year
Recurrent venous thromboembolism† 73 6.5 57 4.8 0.74 (0.52–1.05) 0.09
Deep-vein thrombosis only 43 3.8 39 3.3 0.86 (0.56–1.33) 0.50
Distal 14 11
Proximal 38 30
Other site 2 3
Pulmonary embolism with or without 
deep-vein thrombosis
30 2.7 18 1.5 0.57 (0.32–1.02) 0.06
Major vascular event‡ 88 8.0 62 5.2 0.66 (0.48–0.92) 0.01
Myocardial infarction 6 2
Stroke 5 4
Cardiovascular death 8 4
Bleeding 8 0.6 14 1.1 1.73 (0.72–4.11) 0.22
Major 6 8
Clinically relevant nonmajor 2 6
Major vascular event, major bleeding,  
or death from any cause
99 9.0 71 6.0 0.67 (0.49–0.91) 0.01
Death from any cause 18 16
Pulmonary embolism 1 1
Myocardial infarction 2 2
Other cardiovascular cause including 
sudden death of uncertain cause
5 1
Cancer 4 6
Bleeding 2 0
Other noncardiovascular cause 4 6
* Only the first event for each patient is counted in each row; the event rate was averaged over the study period (median, 
37.2 months).
† The event rate for venous thromboembolism in the first year was 10.6% with placebo, as compared with 4.9% with aspirin.
‡ The outcome of major vascular events was a composite of recurrent venous thromboembolism, myocardial infarction, 
stroke, or cardiovascular death.
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thromboembolism with aspirin is consistent with 
results from the recently reported WARFASA 
study,14 which showed a reduction of 42% (95% 
CI, 7 to 64) in the rate of recurrence of venous 
thromboembolism.
With fewer patients recruited than originally 
planned, the ASPIRE trial by itself was not pow-
ered to show a significant reduction in the pri-
mary outcome, but when combined, as prospec-
tively planned, with the WARFASA study (in which 
the patients had baseline characteristics that were 
similar to those of the ASPIRE patients),14 a clear 
effect is evident. The combined results of the 
WARFASA and ASPIRE trials show a highly sig-
nificant reduction of 32% in the rate of recurrence 
of venous thromboembolism (P = 0.007) and a re-
duction of 34% in the rate of major vascular events 
(P = 0.002), with no excess of bleeding (Fig. 2).
Owing to the relatively high rate of discon-
tinuation of the study drug in the ASPIRE study, 
the estimated treatment effect is likely to have 
underestimated the potential benefit of aspirin 
therapy. The estimated effect in the ASPIRE study 
was 35% for patients while they were receiving 
aspirin, an estimate that is consistent with the 
intention-to-treat estimate in the ASPIRE study 
after adjustment for nonadherence and is also 
consistent with the intention-to-treat estimate 
from the WARFASA trial.
For patients who discontinue anticoagulation, 
the risk of a late recurrence of venous thrombo-
embolism after a first unprovoked event remains 
high: approximately 10% in the first year and 30% 
after 10 years.1-4 Recurrent venous thromboembo-
lism is associated with a case fatality rate of 5 to 
10%4,19,20 and a risk of post-thrombotic syndrome 
that is increased by a factor of 6.1,21,22 Treatment 
with vitamin K antagonists prevents the recurrence 
of venous thromboembolism, but many patients 
are unwilling to accept extended therapy because 
of the risk of bleeding and the inconvenience.
In this context, aspirin, although substantially 
less effective than warfarin,5 provides an attrac-
tive alternative because it is simple and inexpen-
sive and its safety profile is well documented. 
Patients who have had a first unprovoked event 
of venous thromboembolism appear to be at 
greater risk for arterial thrombosis and cardio-
vascular death,15,16 and an added appeal of aspi-
rin is that it has been associated with an overall 
reduction in the risk of major thrombotic events 
(arterial and venous) and cardiovascular death. 
The ASPIRE study suggests that for every 1000 
patients treated for 1 year, aspirin can be ex-
0.5 1.0 2.0 5.0
Placebo BetterAspirin Better
Venous thromboembolism
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WARFASA
Pooled
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WARFASA
Pooled
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Placebo Hazard Ratio (95% CI)AspirinOutcome and Study
0.74 (0.52–1.05)
1.47 (0.70–3.08)
0.98 (0.24–3.96)
1.72 (0.72–4.11)
0.66 (0.51–0.86)
0.67 (0.43–1.03)
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Figure 2. Hazard Ratios for Venous Thromboembolism, Major Vascular Events, and Clinically Relevant Bleeding.
The number of events of venous thromboembolism, major vascular events, and clinically relevant bleeding and the associated hazard ratios 
in the Aspirin to Prevent Recurrent Venous Thromboembolism (ASPIRE) study and the Warfarin and Aspirin (WARFASA) study are shown 
with data from each study separately and with pooled data. Venous thromboembolism refers to the first recurrence of symptomatic deep-
vein thrombosis or pulmonary embolism. The outcome of major vascular events is a composite of venous thromboembolism, myocardial 
infarction, stroke, or cardiovascular death. Clinically relevant bleeding includes major or clinically relevant nonmajor bleeding.
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pected to be associated with 17 fewer episodes of 
recurrent venous thromboembolism and 28 fewer 
major thrombotic events, at the cost of 5 nonfa-
tal bleeding episodes.
In conclusion, the findings of the ASPIRE study, 
especially when considered together with data 
from the WARFASA study, provide consistent evi-
dence that low-dose aspirin is beneficial in pre-
venting recurrent venous thromboembolism and 
major vascular events in patients who have had 
a first episode of unprovoked venous thrombo-
embolism. Thus, aspirin is an attractive option 
for such patients once they have completed an 
initial course of anticoagulation therapy.
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